hypoxoside

02/01/2015 - "Selective ROS-dependent p53-associated anticancer effects of the hypoxoside derivative rooperol on human teratocarcinomal cancer stem-like cells."
01/01/2010 - "IC50 values of hypoxoside and rooperol were determined against the HeLa, HT-29, and MCF-7 cancer cell lines, and peripheral blood mononuclear cells. "
09/01/1995 - "A phase I trial of hypoxoside as an oral prodrug for cancer therapy--absence of toxicity."
09/01/1995 - "Morphological characterisation of the cell-growth inhibitory activity of rooperol and pharmacokinetic aspects of hypoxoside as an oral prodrug for cancer therapy."
02/01/2015 - "We therefore analyzed the antineoplastic activity of rooperol, the aglycone of the plant-derived compound hypoxoside, on a model of Oct4-expressing cancer stem-like cell, i.e. "

09/01/1995 - "To study the pharmacokinetic behaviour of hypoxoside taken orally by 24 patients with lung cancer. "
09/01/1995 - "The pharmacokinetic behaviour of hypoxoside taken orally by patients with lung cancer in a phase I trial."
09/01/1995 - "To assess the toxicity of hypoxoside taken orally by 24 patients with lung cancer. "

09/01/1995 - "The latter catalyses hypoxoside conversion to its cytotoxic aglucone, rooperol, which, when tested as a pure chemical, caused 50% inhibition of BL6 melanoma cell growth at 10 micrograms/ml. Light and electron microscopy revealed that the cytotoxic effect of rooperol manifested as vacuolisation of the cytoplasm and formation of pores in the plasma membrane. "
02/01/1994 - "Gel chromatography of FBS indicated the presence of beta-glucosidase activity with an apparent molecular mass of 29 kDa. In McCoy's 5A medium supplemented with non-heat inactivated FBS, the diglucoside hypoxoside ([E]-1,5-bis[4'beta-D-glucopyranosyloxy-3'-hydroxyphenyl]pent-4-en - 1-yne) showed cytotoxicity toward B16-F10-BL-6 mouse melanoma cells. "
02/01/1994 - "beta-Glucosidase activity in fetal bovine serum renders the plant glucoside, hypoxoside, cytotoxic toward B16-F10-BL-6 mouse melanoma cells."

10/01/2016 - "Hypoxoside and hyperoside have shown selective cytotoxicity at IC50 values of ∼25 and 50μM against INS-1 and MIA PaCa-2 pancreatic cancer cells, respectively. "
10/01/2016 - "The apoptotic and autophagic properties of two natural occurring prodrugs, hyperoside and hypoxoside, against pancreatic cancer cell lines."

09/01/1995 - "Nineteen patients on hypoxoside therapy survived for an average of 4 months with progression of their primary tumours and metastases, while 5 survived for more than a year. "